sulfinpyrazone has been researched along with Psoriasis in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuzell, WC | 1 |
| Seebach, LM | 1 |
| Glover, RP | 1 |
| Jackman, AE | 1 |
1 trial available for sulfinpyrazone and Psoriasis
| Article | Year |
|---|---|
Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.
Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Arthritis, Rheumatoid; Clinical Trials as Topic; Duod | 1966 |